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The kinase inhibitor p27Kip1 regulates the G1 cell
cycle phase. Here, we present data indicating
that the oncogenic kinase Src regulates p27
stability through phosphorylation of p27 at tyro-
sine 74 and tyrosine 88. Src inhibitors increase
cellular p27 stability, and Src overexpression
accelerates p27 proteolysis. Src-phosphory-
lated p27 is shown to inhibit cyclin E-Cdk2
poorly in vitro, and Src transfection reduces
p27-cyclin E-Cdk2 complexes. Our data indi-
cate that phosphorylation by Src impairs the
Cdk2 inhibitory action of p27 and reduces its
steady-state binding to cyclin E-Cdk2 to facili-
tate cyclin E-Cdk2-dependent p27 proteolysis.
Furthermore, we find that Src-activated breast
cancer lines show reduced p27 and observe
a correlation between Src activation and
reduced nuclear p27 in 482 primary human
breast cancers. Importantly, we report that in
tamoxifen-resistant breast cancer cell lines,
Src inhibition can increase p27 levels and re-
store tamoxifen sensitivity. These data provide
a new rationale for Src inhibitors in cancer
therapy.
INTRODUCTION
Mammalian cell proliferation is tightly regulated by the
sequential activation of cyclin-dependent kinases (Cdks)
(Sherr and Roberts, 1999). The Cdk inhibitor, p27, was
initially identified in cells arrested by transforming growth
factor b (TGF-b), by contact inhibition, and by lovastatin
(Polyak et al., 1994; Hengst et al., 1994; Slingerlandet al., 1994; Koff et al., 1993). p27 is ubiquitously ex-
pressed and binds cyclin-Cdk2 to inhibit kinase activity.
p27 is maximal in quiescence, and mitogen-stimulated
p27 loss during G0 to S phase progression leads to cyclin
E-Cdk2 activation. Several mechanisms regulate p27
levels to control cell proliferation. p27 translation is maxi-
mal in G0 and falls abruptly with G0 exit and during G1 pro-
gression (Gopfert et al., 2003; Hengst and Reed, 1996;
Agrawal et al., 1996). At least four pathways regulate
p27 degradation. In late G1 through S and into M phase,
p27 is degraded by the SCFSkp2 ubiquitin ligase, whose
interaction with p27 is activated by cyclin E-Cdk2-
dependent p27 phosphorylation at T187 (Pagano et al.,
1995; Sheaff et al., 1997; Vlach et al., 1997; Montagnoli
et al., 1999). In early G1, T187-independent p27 proteoly-
sis occurs by both Skp2-dependent (Malek et al., 2001)
and Skp2-independent (Hara et al., 2001) pathways. In
early G1, p27 phosphorylation at S10 promotes p27-
CRM1 binding and nuclear export (Rodier et al., 2001;
Ishida et al., 2002; Connor et al., 2003). Proteolysis of
cytoplasmic p27 in G1 involves KPC1 ubiquitin ligase
(Hara et al., 2005; Kamura et al., 2004). Rapid S10-
independent p27 proteolysis may also occur in the
nucleus in early G1 (Rodier et al., 2001). In quiescent cells,
p27 proteolysis requires an intact p27-cyclin-Cdk binding
motif (Besson et al., 2006).
p27 levels regulate cell proliferation and differentiation.
p27 null animals exhibit multiorgan hyperplasia (Fero
et al., 1996; Kiyokawa et al., 1996; Nakayama et al.,
1996), and p27+/ heterozygous animals are tumor prone
(Fero et al., 1998). While normal quiescent epithelial tis-
sues express high p27 (Catzavelos et al., 1997), reduced
p27 protein is observed in up to 60% of primary human
breast and other cancers in association with poor patient
outcome (Alkarain et al., 2004). Several oncogenic
pathways activate p27 proteolysis in cancers (Liang and
Slingerland, 2003). Human breast cancers frequently
show EGFR overexpression or Her2/ErbB2 amplification
(Tsutsui et al., 2002; Nicholson et al., 1990; Slamon et al.,Cell 128, 281–294, January 26, 2007 ª2007 Elsevier Inc. 281
1987). Overexpression of EGFR or Her2 increases p27
proteolysis in cell lines (Lane et al., 2000; Yang et al.,
2000; Lenferink et al., 2000).
Activated EGFR family receptor tyrosine kinases (RTK)
recruit and activate cSrc, and cSrc in turn further activates
RTKs, stimulating cell proliferation (Ishizawar and Par-
sons, 2004). Drug-mediated cSrc inhibition blocks the
effects of EGFR and Her2 on cell proliferation (Belsches-
Jablonski et al., 2001; Biscardi et al., 1999). cSrc is also
activated by liganded estrogen receptor (ER) in human
breast cancer cells. Estrogen:ER binding stimulates rapid,
transient recruitment of cSrc, Shc activation, and MAPK
signaling (Migliaccio et al., 1996). Estrogen:ER-stimulated
Src further recruits RTKs, Her2, EGFR (Chu et al., 2005),
and IGF-1R (Song et al., 2004), to promote cell cycle
progression.
We recently demonstrated a novel Lyn- and Bcr-Abl-
mediated tyrosine phosphorylation of p27 that contributes
to p27 proteolysis (Grimmler et al., 2007 [this issue of
Cell]). Up to 60% of human breast cancers express the
ER, and in these, estrogen is mitogenic. Estrogen-stimu-
lated breast cancer proliferation requires a rapid loss of
p27 through proteolysis (Cariou et al., 2000). Given the on-
cogenic role of Src in breast cancer and its rapid activation
by RTKs and estrogen:ER, we investigated whether Src-
mediated tyrosine phosphorylation of p27 may contribute
to p27 proteolysis in breast cancer cell proliferation.
Here we present evidence that cSrc phosphorylates
p27 on tyrosine 74 (Y74) and tyrosine 88 (Y88). p27 phos-
phorylation by Src reduced the cyclin E-Cdk2 inhibitory
action of p27 in vitro. Src induction increased pT187p27
and reduced the t1/2 of p27. cSrc activation was correlated
with low nuclear p27 in primary human breast cancers.
Mitogen stimulation of quiescent cells rapidly activated
cSrc, and p27 binding to cSrc preceded loss of cyclin
E-Cdk2 from p27 in late G1. These data support a model
in which cSrc-mediated tyrosine phosphorylation of p27
reduces its inhibitory action on cyclin E-Cdk2, facilitating
subsequent p27 proteolysis.
RESULTS
Src Phosphorylates p27 In Vitro
Estrogen stimulates quiescent ER-positive breast cancer
cells to rapidly degrade p27 and enter cell cycle (Cariou
et al., 2000). Estrogen-bound ER stimulates rapid, tran-
sient cSrc activation (Migliaccio et al., 1996; Song et al.,
2004). To investigate if cSrc contributes to estrogen-medi-
ated p27 proteolysis, we assayed if Src could phosphory-
late p27. Purified recombinant activated Src phosphory-
lated recombinant His-p27, and this was inhibited by the
Src inhibitor, PP1 (Figure 1A). Recombinant WT Src could
also phosphorylate p27 (data not shown). To assay the rel-
ative contributions of three tyrosines, Y74, Y88, and Y89,
to Src phosphorylation of p27, single, double, and triple
p27 mutations were generated converting tyrosines to
phenylalanine. Mutant p27 and p27WT were compared282 Cell 128, 281–294, January 26, 2007 ª2007 Elsevier Inc.Figure 1. Src Preferentially Phosphorylates p27 at Y74 and
Y88 In Vitro
(A) His-p27WT reacted with Src kinase with or without PP1.
(B) His-p27WT and p27 mutants reacted with Src kinase per Experi-
mental Procedures. Radioactivity in autophosphorylated Src (pSrc)
or p27 (32P-His-p27) quantitated by phosphoimager and His-p27 input
are shown.
(C) Quantitation of triplicate Src kinase assays (means ± SEM).
(D) His-p27WT and p27 mutants reacted with Yes kinase per Experi-
mental Procedures. Radioactivity in Yes (pYes) or p27 (32P-His-p27)
quantitated by phosphoimager and His-p27 input are shown.
(E) Quantitation of triplicate Yes kinase assays (means ± SEM).
Figure 2. Phosphorylation by Src Re-
duces p27 Inhibitory Action on Cyclin
E-Cdk2
(A) His-p27WTwas phosphorylated in vitro with
activated Src. Mock-treated (p27) or Src-
treated pY-p27 was incubated with cyclin E-
Cdk2 and H1 kinase activity assayed. Equal in-
put of mock versus Src treated p27 is shown.
(B–E) (B) His-p27WT incubated without Src (no
Src), with inactive Src (dead Src), and with ac-
tive Src is shown. pY-p27was precipitated with
apY-4G10. Equal amounts of p27 from (B) were
incubated with cyclin E-Cdk2. (C) p27, (D)
Cdk2, and (E) cyclin E were precipitated and
associated proteins blotted.as substrates in Src kinase assays. Src autophosphoryla-
tion indicates equal Src input (Figure 1B). Radioactivity in
p27 was quantitated by phosphoimager (Figure 1C). Src-
mediated p27 phosphorylation was reduced by 36%
and 33% in p27Y74F and p27Y88F, respectively, com-
pared to p27WT, while that of p27Y89F was only reduced
by 12% (Figure 1C). Loss of Y74 and Y88 (p27Y74FY88F)
reduced p27 phosphorylation by Src by 78%. Thus, these
two sites appear to be preferentially phosphorylated by
Src in vitro (Figure 1C). Loss of potential to phosphorylate
Y89 also reduced phosphorylation of Y74FY89F and
Y88FY89F.
Not all Src family kinases are expressed in mammary
cells. Quantitative real-time PCR of Src, Yes, Fyn, and
Lyn in three breast cancer lines, MCF-7, T-47D, and
MDA-MB-361, showed that Yes expression was higher
or comparable to that of cSrc. Fyn and Lyn mRNA were
detectable but several logs lower in magnitude (see
Figure S1 in the Supplemental Data available with this ar-
ticle online). As for Src, Yes kinase assays showed that
phosphorylation of p27 by Yes was reduced bymutational
loss of Y74 and Y88 phosphorylation, while Y89F only
modestly attenuated phosphorylation by Yes (Figures 1D
and 1E).Tyrosine-Phosphorylated p27 Is a Poor Inhibitor
of Cyclin E-Cdk2
The crystal structure of p27-cyclin A-Cdk2 shows that
Y74, Y88, and Y89 of p27 interact with Cdk2 and not
with N-terminal truncated cyclin A. Y88 is buried in the
catalytic cleft of Cdk2, but Y74 and, to a lesser extent,
Y89 also form contacts with Cdk2 (Russo et al., 1996).
Since Y88 impedes ATP binding to Cdk2, structural data
suggest that tyrosine phosphorylation of p27 would impair
its inhibition of cyclin-bound Cdk2. To test this, increasing
amounts of mock or Src-phosphorylated His-p27 were
incubated with recombinant cyclin E-Cdk2, and Cdk2
activity was assayed. Src was inactivated by boiling the
Src-p27 reactions, and mock-treated His-p27 was also
boiledprior toaddition tocyclinE-Cdk2 reactions.Tyrosine-
phosphorylated p27 (pY-p27) inhibited cyclin E-Cdk2 less
efficiently than mock-phosphorylated p27 (Figure 2A).
To assay whether the impaired inhibitory function of
pY-p27 correlated with decreased association with cyclin
E-Cdk2, p27 was reacted in vitro with either active re-
combinant Src or Src that had been heat inactivated prior
to reaction with p27 (dead Src) or was subjected to amock
Src reaction. Only active Src treated p27 reactedwith anti-
phosphotyrosine antibody 4G10 (apY-4G10, Figure 2B).Cell 128, 281–294, January 26, 2007 ª2007 Elsevier Inc. 283
Because the in vitro Src kinase reactionwas not complete,
pY-p27 was isolated by immunoprecipitation with apY-
4G10. Equal amounts of mock or Src-treated p27 were
incubated with recombinant cyclin E and Cdk2. Mock-
treated and dead-Src-treated p27 immunoprecipitates
bound equal amounts of cyclin E and Cdk2, while pY-p27
precipitates bound less cyclin E and Cdk2 (Figure 2C).
Less Src-phosphorylated pY-p27 was detected in Cdk2
and cyclin E immunoprecipitates compared to mock or
untreated p27 (Figures 2D and 2E). Thus, the reduced cy-
clin E-Cdk2 inhibitory function of Src-phosphorylated p27
versus unphosphorylated p27 may result in part from its
reduced steady-state binding to this cyclin-Cdk2 target.
Intracellular Tyrosine Phosphorylation of p27
Weand others recently identified tyrosine-phosphorylated
p27 in leukemic cells (Kardinal et al., 2006; Grimmler et al.,
2007). Bcr-Abl and Lyn kinases phosphorylated p27 pre-
dominantly at Y88 in vitro, and in K562 cells, Y88 was
the major tyrosine phosphorylated site in p27 (Grimmler
et al., 2007). Because in vitro kinase assays showed that
p27Y74F had reduced phosphorylation by Src, polyclonal
antibody specific to Y74-phosphorylated p27 (p27pY74)
was generated. ap27pY74 antibody recognized Src-
phosphorylated His-p27WT but not His-p27Y74F (Fig-
ure 3A, left), while apY-4G10 reacted with both p27WT
and p27Y74F after Src kinase reactions in vitro (Figure 3A,
left).
To detect intracellular Y74 phosphorylation of p27,
MCF-7 cells were cotransfected with constitutively active
Src or empty vector and YFPp27. Tyrosine-phosphory-
lated p27 was detectable with apY-4G10 in p27 immuno-
precipitates from Src-transfected but not from mock-
transfected cells (Figure 3A, middle). Similarly, p27pY74
was detected with ap27pY74 antibody only after cSrc
transfection (Figure 3A, right). Endogenous cellular
p27pY74 was also detected with this antibody in the
absence of exogenous Src (see Figure 5E).
To test the preference of Src for the different p27 tyro-
sines in cells, activated Src and YFPp27WT, p27Y74F,
p27Y88F, or p27Y89F were transfected into MCF-7. All
p27 vectors were equally and stably overexpressed (Fig-
ure 3B). p27 precipitates were immunoblotted and re-
acted with apY-4G10, ap27pY74, or antibody to total
p27. Reactivity of p27WT with apY-4G10 and with
ap27pY74 following Src cotransfection was attenuated
by the Src inhibitor, PP1 (Figure 3B).
Transfected p27Y74F and p27Y88F immunoprecipi-
tates were less reactive than YFPp27WT with apY-4G10,
while apY-4G10 reactivity of p27Y89F was not detectably
reduced (Figure 3B). Y74 phosphorylation was detected
in p27Y88F, p27Y89F, and p27WT, but reactivity of
ap27pY74 with p27Y74F showed no increase above non-
specific baseline (Figure 3B). Thus, Y74 and Y88 appear to
be the dominant cSrc phosphorylation sites in vivo. Loss
of Y89 phosphorylation may attenuate Y74 phosphoryla-
tion in vivo and lead to a compensatory increase in Y88
phosphorylation.284 Cell 128, 281–294, January 26, 2007 ª2007 Elsevier Inc.The effect of Src overexpression on p27-cyclin E-Cdk2
complexes was tested. Src transfection with or with-
out PP1 treatment did not affect levels of cellular cyclin
E and Cdk2 or overexpressed YFPp27 (Figure 3C).
YFPp27WT immunoprecipitates contained less bound cy-
clin E and Cdk2 following Src transfection, and this was
abrogated by PP1 (Figure 3D). Similarly, Src transfection
modestly reduced p27 in Cdk2 precipitates, while Cdk2-
bound cyclin E was unaffected (Figure 3E).
Src Effects on Cellular p27 Levels and Stability
Since experiments above involved overexpressed p27,
which could overwhelm cellular p27 proteolysis, effects
of Src on cellular p27 were assayed. cSrc siRNA or Src in-
hibition for 48 hr each increased cellular p27 (Figures 4A
and 4B).
Src is activated in MDA-MB-361 line due to Her2/ErbB2
activation (Belsches-Jablonski et al., 2001). p27 half-life
was assayed by cycloheximide chase in asynchronous
MDA-MB-361 and in cells treated with the Src family ki-
nase inhibitor, AZD0530, for 6 hr. Src inhibition increased
the p27 t1/2 from 4.0 to 9.7 hr (Figure 4C).
To test further the effect of Src on p27 stability, inducible
Src-expressing lines were generated. Cells were serum
and estrogen deprived, and Src was induced or not with
ponasterone A (PA) prior to readdition of estrogen. Estro-
gen stimulation alone, in the absence of added growth
factors, had little effect on p27 levels over 6 hr; however,
Src induction together with estrogen led to more rapid
loss of p27 in two different Src-inducible MCF-7 clones
(shown for MCF-pINDSrc2, Figure 4D). Src induction re-
duced the p27 t1/2 at 6 hr after estrogen addition to 5.8
hr compared to the p27 t1/2 of 9.8 hr in controls treated
with estrogen alone (Figure 4E). T187 phosphorylation of
p27 was more readily detected when starved cells were
treated with estrogen plus Src compared to estrogen
alone (Figure 4F).
These findings support a model in which Src promotes
p27 degradation by decreasing the inhibitory action of
p27 on cyclin E-Cdk2, facilitating cyclin E-Cdk2-depen-
dent p27 phosphorylation and SCFSKP2-mediated p27
proteolysis.
cSrc-p27 Interaction Is Increased in Cancer Lines
with Activated Src
p27-bound cSrc was detected in three breast cancer
lines, MCF-7, T-47D, and MDA-MB-361. Cells with higher
cSrc activity had reduced p27 levels but higher p27-
bound cSrc (Figure 5A).
In contrast to normal mammary epithelial cells in which
p27 shows nuclear localization (Catzavelos et al., 1997),
T-47D and MDA-MB-361 have both nuclear and some
cytoplasmic p27. p27-Src complexes were detected in
nuclear fractions. Nuclear cSrc-p27 complexes were
only minimally detectable in cells deprived of estrogen
and growth factors in 0.1% cFBS for 48 hr (E) but were
readily detected in asynchronous cells in complete me-
dium (E+) (data shown for T-47D, Figure 5B). To confirm
Figure 3. pY74p27 Antibody and In Vivo p27 Phosphorylation by Src
(A) His-p27WT or His-p27Y74F was reacted with Src in vitro. p27 precipitates were blotted with apY-4G10 or ap27pY74 (left). MCF-7 was transfected
with YFPp27WT and empty PCI vector (Src) or PCI-Src-Y530F (Src +). p27 precipitates were blotted with apY-4G10, stripped, and reprobed for p27
(middle panel). pY74p27 was detected in Src-transfected MCF-7 (right panel).
(B) MCF-7 was cotransfected with YFPp27WT or mutant p27 with or without Src. pY-p27 was detected in p27 precipitates with apY-4G10 or
ap27pY74.
(C) Cyclin E, Cdk2, YFPp27, and p27pY74 levels in YFPp27WT transfected MCF-7 with or without Src cotransfection or PP1.
(D and E) p27 (D) and Cdk2 (E) precipitates were resolved and proteins detected by blotting.Cell 128, 281–294, January 26, 2007 ª2007 Elsevier Inc. 285
Figure 4. cSrc Inactivation Increases p27 Levels and Stability, and Src Induction Decreases p27 t1/2
(A) MCF-7 cells transfected with cSrc siRNA or nonspecific controls analyzed for cSrc, 27, and b actin.
(B) cSrc, p27 and b-actin levels with (+) or without () AZD0530 in MDA-MB-361.
(C) Cycloheximide (CHX) chase of p27 in MDA-MB-361 before and 6 hr after AZD0530.
(D) Src was induced in estrogen-starved MCF-pINDSrc2 (E) by ponasterone A (PA+). Six hours after estrogen addition (E+), Src, p27, and b-actin
were assayed.
(E) CHX chase of p27 at 6 hr after estrogen treatment, with or without prior Src induction.
(F) p27pT187, p27, and b-actin at 13 hr after E stimulation, with or without prior Src induction. MG132 was added 6 hr prior to analysis.286 Cell 128, 281–294, January 26, 2007 ª2007 Elsevier Inc.
Figure 5. Src Activation and p27-Src Interaction Increase in Early G1
(A) p27, cSrc, and b-actin, IP Src kinase activities, and p27-bound cSrc in MCF-7, T-47D, and MDA-MB-361.
(B) cSrc, p27, p27-bound cSrc, and nuclear (RCC1), cytoplasmic (tubulin), and membrane (caveolin) markers in subcellular fractions from quiescent
(E) or asynchronous (E+) T-47D.
(C) Estrogen-deprived MCF-7 (t = 0) was stimulated with estradiol and insulin and percent S and protein levels assayed at indicated times.
(D) cSrc activity, p27-bound cSrc, cyclin E, and Cdk2 in lysates from (C) above.
(E) Src, p27, and b-actin in estrogen-starved cells treated with estrogen for 2 hr with (+PA) or without (PA) prior Src induction (left). p27 and Src in
ap27pY74 precipitates (right).Cell 128, 281–294, January 26, 2007 ª2007 Elsevier Inc. 287
the nuclear localization of p27-Src complexes, p27S10A
or p27WT was transfected into MCF-7 with or without
transfection of Src. p27S10A is localized to the nucleus
due to reduced nuclear export (Connor et al., 2003).
p27-bound Src was equally detected in p27S10A and
p27WT complexes (Figure S2).
cSrc-p27 Interaction Precedes p27 Loss
in G1 Progression
Quiescent estradiol-depleted MCF-7 cells enter S phase
within 12 hr of estrogen and insulin addition (Figure 5C)
(Cariou et al., 2000). cSrc was rapidly activated on G0
exit, peaking at 1 hr, and fell to baseline by 3–6 hr (Fig-
ure 5D). p27 levels fell during G1 progression, while
cSrc, cyclin E, and Cdk2 levels did not vary (Figure 5C).
Rapid Src activation correlated with increased Src-p27
coprecipitation and preceded the reduction of total p27
and loss of p27-bound cyclin E and Cdk2 as cells entered
S phase (Figure 5D).
To demonstrate Y74 phosphorylation of endogenous
cellular p27, MCF-pINDSrc2 cells were estrogen de-
prived, and the Src was induced or not by PA. Cells
were then treated with estrogen for 2 hr to stimulate en-
dogenous cSrc. ap27pY74 precipitates were resolved
and immunoblotted for p27 and Src. Following estrogen
stimulation of starved cells, Y74 phosphorylation of cellu-
lar p27 was detected, and this was increased by Src
induction (Figure 5E). Src-pY-p27 complexes were in-
creased in Src-induced cells (Figure 5E).
cSrc Activation in Human Breast Cancers
Is Correlated with Low Nuclear p27
To test if cSrc activation is associated with reduced p27 in
primary human breast cancers, p27 and phosphorylated,
activated cSrc (detectedwith an anti-pY416-Src antibody)
were assayed by immunohistochemistry in 482 tumors.
Thirty-seven percent showed reduced nuclear p27 levels.
Little or no cSrc activation (score 0) was detected in 23%
of tumors. cSrc activation (scores of 2 or 3) was detected
in 39% of tumors. Normal mammary duct tissue controls
present on all tissue microarrays showed no cSrc activa-
tion. The correlation of low p27 with cSrc activation and
other clinical and pathologic variables is shown in Table 1.
As in prior studies, reduced p27 was strongly correlated
with estrogen and progesterone receptor-negative status
and was associated with increased tumor size, high tumor
grade (a measure of dedifferentiation), and tumor inva-
siveness as indicated by more lymph nodes affected
and intratumoral invasion of the lymphovascular spaces
(LVI). Reduced p27 was statistically correlated with acti-
vated Src when all four Src scoring levels were used (p =
0.05), and this was more significant when Src activity
was categorized as high (scores 2–3) or low (scores
0–1), p = 0.01 (Table 1). Cancers with low p27 and high
pY416-Src immunoreactivity (left panels) and high p27
with low pY416-Src (right panel) are shown in Figure S3.288 Cell 128, 281–294, January 26, 2007 ª2007 Elsevier Inc.Table 1. Correlation of p27 Levels with Src Activation
and Other Clinical/Pathologic Variables in 482 Primary
Human Breast Cancers
Variables Low p27 High p27 P Valuea
n = 177 n = 305
n (%) n (%)
Tumor Grade
1 9 (6.8) 25 (10.3)
2 56 (42.1) 126 (52.1)
3 68 (51.1) 91 (37.6) 0.04
Missing 44 63
Nodal Status
Negative 55 (35.5) 119 (48.0)
Positive 100 (64.5) 129 (52.0) 0.01
Not tested 22 57
ERb
Negative 78 (44.3) 60 (19.9)
Positive 98 (55.7) 241 (80.1) <104
Missing 1 4
PRc
Negative 84 (53.9) 77 (29.0)
Positive 72 (46.2) 189 (71.1) <104
Missing 21 39
LVId
Not present 83 (55.7) 178 (65.0)
Present 66 (44.3) 96 (35.0) 0.06
Unknown/missing 28 31
Menopausal Status
Post 95 (54.0) 187 (61.5)
Pre 81 (46.0) 117 (38.5) 0.11
Missing 1 1
Src
0 40 (22.6) 73 (23.9)
1 55 (31.1) 126 (41.3)
2 51 (28.8) 72 (23.6)
3 31 (17.5) 34 (11.2) 0.05
Src
0 or 1 95 (53.7) 199 (65.3)
2 or 3 82 (46.3) 106 (34.7) 0.01
aChi-square test to compare the frequency and t test to com-
pare the mean.
b ER, estrogen receptor.
c PR, progesterone receptor.
d LVI, lymphovascular invasion.
Src Inhibition and Tamoxifen Cooperate to Inhibit
Cell Cycle Progression
Tamoxifen is an ER-blocking drug that arrests sensitive
ER-positive breast cancer cells in G0/G1 by inhibiting es-
trogen-stimulated p27 proteolysis. p27 expression is re-
quired for arrest by tamoxifen (Cariou et al., 2000). Over-
activation of RTKs can confer antiestrogen resistance
(Benz et al., 1992; Pietras et al., 1995; Donovan et al.,
2001) and also recruit and activate Src (Biscardi et al.,
1999; Tice et al., 1999). Since Src-dependent p27 phos-
phorylation impaired its cyclin-Cdk2 inhibitory action, we
tested if Src inhibition could restore tamoxifen responsive-
ness to resistant cells. MDA-MB-361 has high cSrc activ-
ity (Figure 5A), fails to arrest upon estrogen deprivation,
and is resistant to tamoxifen-mediated G1 arrest. These
cells showed only a partial G1 arrest after 48 hr of treat-
ment with an ER-saturating dose of tamoxifen. Increasing
tamoxifen or treatment with the irreversible ER blocker,
fulvestrant, failed to cause G1 arrest (data not shown).
AZD0530 (AstraZeneca Ltd.) is a potent, specific drug
inhibitor of Src family kinases (Ple et al., 2004) in clinical tri-
als for cancer in humans. While AZD0530 inhibits both Src
family and Abl kinases, Abl is not expressed in breast can-
cers. Asynchronous MDA-MB-361 cells were treated with
AZD0530, tamoxifen alone, or both together. The 1 mM
dose of each drug caused partial G1 arrest with the per-
cent of S phase falling from 43% to 30% and 20%, re-
spectively, after 48 hr. AZD0530 and tamoxifen together
reduced the percent of S phase cells to 4% (Figure 6A).
Each drug alone increased p27 by less than 2-fold,
whereas both drugs together increase p27 >4-fold
(Figure 6B). Cyclin E-Cdk2-bound p27 increased 2.3-
fold with AZD0530, 1.7-fold with tamoxifen alone, and 5-
fold with both drugs together (Figure 6C) with loss of cyclin
E-cdk2 activity (data not shown). Thus, Src inhibition re-
stored p27 action and tamoxifen-mediated G1 arrest.
Src inhibitionwithAZD0530also restored response to ta-
moxifen in two other ER-positive, partially resistant breast
cancer lines, T-47D andBT474. In two lines with onlymod-
est Src activation (MCF-7R and ZR75-1), AZD0530 did not
augment tamoxifen responses (see Table S1).
DISCUSSION
Regulation of p27 Levels
p27 is frequently inactivated in human cancers through
accelerated p27 proteolysis or sequestration in the cyto-
plasm. Reduced p27 is an independent marker of poor
breast cancer prognosis (Alkarain et al., 2004). In normal
cells, p27 levels fall rapidly as cells progress from G1 to
S phase. However, a major mechanism of p27 proteolysis
involves its phosphorylation by the very kinase it inhibits.
p27 acts both as an inhibitor and as a substrate of cyclin
E-Cdk2 (Sheaff et al., 1997). While cyclin E-Cdk2 phos-
phorylation of T187 targets p27 for SCFSkp2-mediated
proteolysis in late G1, mechanisms permitting initial cyclin
E-Cdk2 activation in early G1 despite the persistent abun-
dance of its inhibitor have remained obscure. We andothers have postulated that early G1 phosphorylation
events may reduce the affinity of p27 for cyclin E-Cdk2,
promoting p27 dissociation from Cdk2, binding to
CRM1, and export-driven proteolysis of p27 in the cyto-
plasm (Connor et al., 2003; Ishida et al., 2002; Hara
et al., 2001). However, it has been difficult to provide de-
finitive evidence for this in vivo.
Our earlier work showed that TGF-b-resistant cells
(Florenes et al., 1996; Ciarallo et al., 2002) and cancer
cell lines that overexpress oncogenes including ILK,
Figure 6. Src Inhibitor Cooperates with Tamoxifen to Arrest
Antiestrogen-Resistant Breast Cancer Cells
(A) Cell cycle profile in MDA-MB-361 treated with tamoxifen (TAM),
AZD0530, or both for 48 hr.
(B) Cyclin E, Cdk2, and p27 in cells from (A).
(C) Cyclin E-bound Cdk2 and p27.Cell 128, 281–294, January 26, 2007 ª2007 Elsevier Inc. 289
Her2, or MEK exhibit altered p27 phosphoisoforms with
reduced cyclin E-Cdk2 inhibitory function (Radeva et al.,
1997; Donovan et al., 2001; Ciarallo et al., 2002). Such in-
termediate forms of p27 could facilitate the transition of
p27 from inhibitor to substrate of cyclin E-Cdk2. Here
we present evidence that Src-mediated tyrosine phos-
phorylation of p27 reduces its inhibitory function for cyclin
E-Cdk2.
Src Activation in Cancer
cSrc activates mitogenic signaling in normal and malig-
nant cells to regulate cell proliferation, survival, metasta-
sis, and angiogenesis (Ishizawar and Parsons, 2004;
Thomas and Brugge, 1997). Increased cSrc levels and/
or activity has been observed in many human cancers
when compared to adjacent normal tissues, including
breast, prostate, lung, colorectal, and ovarian carcinomas
(Chen et al., 2006; Irby and Yeatman, 2000; Biscardi et al.,
2000), and are often associated with increased disease
stage (Frame, 2002). We observed Src activation in 39%
of 482 primary human breast cancers.
Src activation in cancers results from oncogenic activa-
tion of RTKs, including EGFR, Her2/ErbB2, IGF-1R,
colony stimulating factor-1, and hepatocyte growth factor
receptor. Reduced phosphorylation of its negative regula-
tory site, SrcY530, can also activate Src (Chen et al.,
2006). Activating Src mutations are rare in human cancers
and in colon cancer correlate with metastatic progression
(Irby et al., 1999). EGFR and Her2/ErbB2 both bind Src to
catalyze mutual kinase activation. cSrc and EGFR family
members are frequently overexpressed in primary human
breast cancers (Ishizawar and Parsons, 2004).
Src Regulates p27
Here we demonstrate cSrc-mediated p27 phosphoryla-
tion in vitro and in vivo at both Y74 and Y88. Mutation con-
verting p27 Y89 to F reduced in vitro Src phosphorylation
of p27 by only 12%, and p27Y89F cotransfected with Src
showed no reduction in reactivity with apY-4G10 antibody
in vivo compared to p27WT. While loss of Src phosphory-
lation of Y89 showed little effect in vivo, this site maymod-
ulate phosphorylation of Y74 and Y88.
Both putative tyrosine phosphorylation sites, p27Y74
and p27Y88, form contacts with Cdk2. The partial crystal
structure of cyclin A-Cdk2-bound p27 reveals that the re-
gion between Y74 and Y88 of p27 forms a clamp around
the N lobe of Cdk2 (Russo et al., 1996). Y74 is partially bur-
ied in theN-terminal b sheet of Cdk2, forming hydrophobic
interactions with L25, V30, L67, and V79 on the outer sur-
face of the Cdk2 N lobe. The aromatic ring of p27Y88
forms van der Waals contacts to F80, F82, and L134 of
Cdk2, and its hydroxyl group makes two hydrogen bonds
to Cdk2 E81 and L83 (Russo et al., 1996). The side chain of
p27Y88 occupies the catalytic cleft of Cdk2 and mimics
the contacts made by the purine base of ATP (Russo
et al., 1996). NMR data indicate that Y88 phosphorylation
of p27 ejects the 310 helix from the catalytic cleft of Cdk2,
but this phosphorylation alone did not disrupt p27 binding290 Cell 128, 281–294, January 26, 2007 ª2007 Elsevier Inc.to cyclin A-Cdk2 (Grimmler et al., 2007). This would ex-
plain the reduced inhibitory action of p27 toward cyclin
E-Cdk2 following Src kinase pretreatment in vitro.
While Abl and Lyn appear to predominantly phosphory-
late Y88, both Y74 and Y88 were phosphorylated by Src.
Src-phosphorylated p27 showed a decreased steady-
state association with cyclin E-Cdk2 both in vitro and
following cotransfection of p27WT with activated Src
in vivo. Phosphorylation of Y74 together with Y88 may
not only mediate loss of p27 inhibitory activity against cy-
clin E-Cdk2 but also promote dissociation of p27 from the
complex. Thus, different tyrosine kinases may have differ-
ent consequences in vivo on p27 function and stability.
Further studies will be required to elucidate the full struc-
tural implications of these tyrosine phosphorylation events
on p27 function and to define the profile of tyrosine
kinases that regulate these sites in vivo in response to mi-
togen stimulation. In certain cancers, constitutive Y88
phosphorylation, without concurrent Y74 phosphoryla-
tion, may permit activation of p27-associated cyclin-
Cdk2. NMR structural data support this model (Grimmler
et al., 2007).
Estrogen:ER binding has been shown to recruit Src
leading to MEK activation (Migliaccio et al., 1996; Song
et al., 2004), and estrogen also reduces p27 (Cariou
et al., 2000). The present data suggest that estrogen-
dependent Src activation regulates p27 proteolysis. Src
inhibition and siRNA increased cellular p27. Moreover,
both cell lines and primary breast cancers with activated
Src showed reduced p27. Src was rapidly activated bymi-
togen stimulation, and cellular p27-Src coprecipitation
preceded the reduction of p27 and loss of cyclin E-Cdk2
from p27 prior to S phase entrance. Src inhibition pro-
longed the p27 half-life, and Src induction increased cellu-
lar p27pY74 and p27pT187 and reduced p27 half-life.
These data support a model in which tyrosine phosphory-
lation of p27 by Src would reduce p27-mediated inhibition
of cyclin E-Cdk2, liberating this kinase to phosphorylate
its approximated inhibitor at T187, promoting p27 ubiqui-
tination by SCFSkp2 and its degradation (Pagano et al.,
1995; Sheaff et al., 1997; Carrano et al., 1999). Tyrosine
phosphorylation of p27 would thus regulate the transition
of p27 from inhibitor to substrate of cyclin-Cdk2. p27
phosphorylation at T187 by cyclin A-Cdk2 in vitro was en-
hanced by prior Abl-phosphorylation of p27 and followed
a pseudounimolecular mechanism; thus, pY-p27 appears
to be more readily phosphorylated by cyclin-Cdk2 com-
pared to nonphosphorylated p27 (Grimmler et al., 2007).
Src transfection in NIH3T3 and Rat-1 fibroblasts also in-
creased Cdk2 activity and reduced p27 (Riley et al.,
2001; Johnson et al., 1998). Moreover, induced overex-
pression of dominant-negative Src increased p27 t1/2 in
MCF-7 (Gonzalez et al., 2006). The role of cYes in re-
sponse to RTKs and estrogen is less well characterized
than that of cSrc. Given our observation that cYes can
also phosphorylate p27 in vitro, the potential for coopera-
tive effects of cYes and cSrc on p27 function warrants
further investigation.
A Role for Src Inhibitors in Treatment
of Antiestrogen-Resistant Breast Cancer
ER blockade by tamoxifen or estrogen deprivation by
aromatase inhibitors is of therapeutic utility in a majority
of breast cancers that express the ER. p27 is required
for G1 arrest by tamoxifen or estrogen deprivation (Cariou
et al., 2000). Despite initial responses, the development of
antiestrogen resistance limits treatment efficacy. EGFR
and Her2/ErbB2 overexpression can confer tamoxifen re-
sistance in cultured lines (Benz et al., 1992; Pietras et al.,
1995; Donovan et al., 2001). Since these RTKs activate
Src and given our observation that Src impairs the Cdk2
inhibitory action of p27, we tested if Src inhibition could
restore antiestrogen responsiveness to resistant cells.
AZD0530 is a potent, orally available dual inhibitor of Abl
and Src family kinases (Ple et al., 2004). It showed potent
(<mM IC50) antiproliferative activity in 17 human cancer
cell lines and inhibited growth of 6 of 13 xenograft tumor
models tested. AZD0530 inhibits cell motility and invasion
in vitro (Hiscox et al., 2005) and inhibits metastasis in
animal models in vivo (T. Green et al., 2005, American
Association for Cancer Research, abstract).
In three different Src-activated ER-positive breast can-
cer lines, AZD0530 or ER-saturating doses of tamoxifen
each, when given alone, caused partial cell cycle inhibi-
tion. AZD0530 together with tamoxifen increased p27, in-
hibited cyclin E-Cdk2, and causedG1 arrest. In contrast, in
lines lacking Src activation, addition of AZD0530 did not
enhance the antiproliferative effect of tamoxifen. Our anal-
ysis showed a statistical association between low nuclear
p27 and Src activation in 482 primary human breast can-
cers. Of 392 ER-positive cancers assayed, 127 of 339
(37%) showed Src activity scores of 2–3. This proportion
is similar to the fraction of ER-positive breast cancers
that manifest de novo antiestrogen resistance. These
data raise the provocative possibility that Src inhibitors
could restore response to tamoxifen in breast cancers
with Src activation. AZD0530 has shown good bioavail-
ability (T. Green, personal communication) and is in phase
II trials for human cancers. The present data not only iden-
tify a novel mechanism whereby RTKs via Src promote
p27 phosphorylation and proteolysis, they also provide
a rationale for testing Src inhibitors together with anti-
estrogens in xenografts and to further explore their thera-
peutic potential in human breast cancer.
EXPERIMENTAL PROCEDURES
Cell Culture
MCF-7, MDA-MB-361, BT474, T-47D, and ZR75-1 were cultured as in
Cariou et al. (2000). MCF-7 cells were depleted of estradiol using 5%
charcoal-stripped FBS for 48 hr. Cell cycle entry was stimulated by
estradiol (1 3 108 M) and insulin (10 mg/ml).
Plasmids, Site-Directed Mutagenesis, Recombinant Protein,
and Transfection
Conversion of tyrosine 74, 88, 89, 74/88, 74/89, and 74/88/89 to phe-
nylalanine in pET28a p27WT used QuikChange Site-Directed Muta-genesis Kit (Stratagene). Recombinant p27 proteins were purified by
nickel agarose FPLC.
TheWT and mutant p27 cDNAs were subcloned into pEYFP-C1 and
transfected into MCF-7 as in Connor et al. (2003). Fifty nanomolars of
cSrc siRNA and nonspecific control oligos (Dharmacon) were trans-
fected using Lipofectamine 2000 (Invitrogen). Activated human cSrc
PCI-Src Y530F was provided by D. Fujita (University of Calgary).
Human Cdk2 and cyclin E were produced from baculovirus-infected
Sf9 cells as in Ciarallo et al. (2002).
Antibodies
Antibody sources were the following: p27 (Transduction Labs and
Santa Cruz), anti-PSTAIRE (Cariou et al., 2000), Cdk2 (Santa Cruz),
cyclin E1 mAbs (E12 and E172) from E. Harlow (Boston, MA), anti-
phosphotyrosine Ab4G10 (Upstate), Src GD11 (Upstate), and b actin
(Sigma). The polyclonal apY74p27 antibody was developed by Invitro-
gen/Zymed using a cys-KLH-coupled peptide HKPLEGKpYEWQE for
rabbit immunization and purified by column chromatography.
Assays of Immunoprecipitable and Recombinant Src
Kinase Activity
Cells were lysed in 4C NP40 lysis buffer (Cariou et al., 2000) and Src
precipitated with GD11 (Upstate). IP cSrc kinase assays were as de-
scribed (Egan et al., 1999).
For in vitro Src kinase reactions, 400 ng recombinant cSrc (Upstate)
was reacted with (10 mg) his-p27WT or pY-p27 mutant with 2 mM ATP
for 2 hr in Src kinase buffer as in Egan et al. (1999). Radioactivity in p27
was quantitated by Molecular Dynamics PhosphorImager and Image-
Quant software.
Src Effects on p27-Cyclin E-Cdk2 Binding and Cyclin
E-Cdk2 Activity
pY-p27 was isolated from Src kinase reactions by precipitation with
mAb4G10. Recombinant cyclin E-Cdk2 was mixed with equal
amounts of pY-p27 or with p27 that was either mock treated or treated
with Src inactivated by PP1 and boiled for 5 min (dead Src). Cyclin E,
Cdk2, and p27 immune complexes were analyzed by western blot.
Cyclin E-Cdk2 activity was assayed per Cariou et al. (2000).
Immunoblotting and Immunoprecipitation
Cells were lysed in 4C 0.1%NP40, 1%NP40, or RIPA buffer. Western
assays of cyclin E, p27, and Cdk2 and IP-western assays of cyclin E,
Cdk2, and p27 complexes were as in Donovan et al. (2001). Cellular
Src was detected in p27 precipitated from 1 mg lysate. Nuclear and
cytoplasmic subcellular fractionation was as described (Connor
et al., 2003).
Inducible Src Lines and Cycloheximide Chase
Src Y530F cDNA was cloned into pIND (Invitrogen) and transfected
into MCF-7 with an integrated pVgRXR vector (Invitrogen). Src was
induced with 2 mM PA. Two clones (MCF-pINDSrc2 and MCF-
pINDSrc12) had no Src expression above baseline without PA but
high Src levels 8–24 hr after PA. These were arrested by estrogen dep-
rivation as above for 72 hr and 2 mMPA added or not for the last 10 hr of
estrogen deprivation. Cells were then transferred to 0.1% cFBS, 10 nM
estradiol added for 6 hr, and p27 t1/2 assayed by cycloheximide.
Cycloheximide 100 mg/ml was added and the decrease in p27 quanti-
tated over time. PA alone did not alter p27 levels in parental MCF-7.
For detection of T187 phosphorylated p27, at 6 hr after estrogen ad-
dition with or without prior induction of Src, cells were treated with
MG132 for a further 6 hr and then pT187p27 blotted.
For Src effects on p27 stability, MDA-MB361 was treated for 6 hr
with 1 mM AZD0530 prior to CHX chase. p27 was quantitated by den-
sitometry in multiple ECL exposures of different biologic experiments
and p27 t1/2 quantitated by linear regression.Cell 128, 281–294, January 26, 2007 ª2007 Elsevier Inc. 291
Breast Cancer Patient Population and Tumor
Immunohistochemistry
The Henrietta Banting Breast Tumor Bank contains paraffin-embed-
ded breast cancers resected between 1987 and 1997 at Women’s
College Hospital, Toronto, Canada. The database includes clinical
and pathologic features at diagnosis and patient outcome. A tissue
microarray containing more than 500 primary cancers was con-
structed (Kononen et al., 1998) by using three different, 0.6 mm diam-
eter cylinders from each original tumor block.
p27 immunohistochemistry was as described (Catzavelos et al.,
1997) by using monoclonal p27Kip1 antibody and biotin-labeled
anti-mouse IgG, preformed avidin-biotin-peroxidase complex, and
diaminobenzidine (AB) substrate. p27 was scored as percent of tumor
nuclei positive (0%–24% = low p27 orR25% = high p27) (C. Catzave-
los and J.S., unpublished data).
Activated Src was detected by blocking with 5% H2O2 and 10%
normal goat serum followed by reaction with 1:33 dilution of anti-
phospho-cSrc (pY416-Src) (Stressgen) overnight at 4C, reaction
with biotinylated goat anti-rabbit antibody (Zymed), and then strepta-
vidin peroxidase conjugate and diaminibenzidnine. Of 523 cases
retrieved, 16 lacked Src staining, and in 25 the p27 stain was inade-
quate due to poor tissue fixation or no tumor on the TMA. The predom-
inant staining intensity was scored as follows: 0, no staining; 1, weak
staining; 2, moderate staining; and 3, intense staining. Themean score
for three cores for each tumor was used in statistical analysis. Institu-
tional ethics board approval was obtained prior to study initiation. Cor-
relations between p27 and pY416-Src scores and other clinical-path-
ologic data in 482 tumors were assayed using Fischer’s exact test to
compare means and chi-square analyses to compare frequencies.
Flow Cytometric Analysis
BrdU pulse labeling and flow cytometry were as in Cariou et al. (2000).
Cell Cycle Effects of Tamoxifen and AZD0530
AZD0530 (AstraZeneca) was used as described (Ple et al., 2004). The
lowest dose of 4-OH-TAM or AZD0530 to cause maximal cell cycle
inhibitionwhen used alone was used for assays of both drugs together.
Cells were incubated with either vehicle alone, 1 mM 4-OH-TAM, 1 mM
AZD0530, or both drugs together and recovered 48 hr later for flow
cytometry and protein analysis.
Supplemental Data
Supplemental Data include Supplemental Experimental Procedures,
three figures, and one table and can be found with this article online
at http://www.cell.com/cgi/content/full/128/2/281/DC1/.
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